M. Ali Nasseri | Medicine and Health Sciences | Innovative Research Award

Innovative Research Award

M. Ali Nasseri Β· Technical University of Munich Β· Germany

Researcher profile
M. Ali Nasseri
Affiliation Technical University of Munich
Country Germany
Scopus ID 55849349900
Documents 78
Citations 1,160
h-index 19
Subject area Medicine and Health Sciences
Event International Research Hypothesis Excellence Award
ORCID 0000-0002-9764-5731

Innovative Research Award is the title of this academic recognition profile concerning M. Ali Nasseri, whose supplied researcher information associates him with the Technical University of Munich in Germany and the subject area of Medicine and Health Sciences. The profile presents the bibliometric indicators provided for the researcher and outlines considerations relevant to evaluating research contributions in the context of the International Research Hypothesis Excellence Award. The information should be checked against authoritative researcher records before being used for formal recognition or bibliometric comparisons.[1][2]

Abstract

This article presents an academic recognition profile for M. Ali Nasseri in the context of the Innovative Research Award and the International Research Hypothesis Excellence Award. The supplied profile data lists 78 documents, 1,160 citations, and an h-index of 19, with Medicine and Health Sciences identified as the relevant subject area. These bibliometric values provide a quantitative starting point for describing research output and citation activity. However, the figures alone do not establish the originality, methodological quality, clinical relevance, or practical impact of individual studies. A comprehensive assessment would also require examination of verified publications, research methods, scholarly contributions, and independent evaluation criteria.[1][3]

Keywords

Innovative Research Award; M. Ali Nasseri; Medicine and Health Sciences; research evaluation; bibliometrics; citation analysis; h-index; scholarly publications; research impact; International Research Hypothesis Excellence Award; academic recognition; scientific innovation.

Introduction

Research recognition programs provide a framework for identifying and acknowledging scholarly contributions across scientific disciplines. In medicine and health sciences, meaningful evaluation can involve the originality of research questions, the robustness of study design, the reproducibility of findings, ethical research practices, and the potential contribution of results to clinical or public health knowledge. Bibliometric measures can support this process, but they should be interpreted alongside qualitative evidence and the context in which the research was produced.[3][4]

This profile organizes the supplied information about M. Ali Nasseri into a structured academic overview. It is intended as a presentation of researcher information and award-related considerations, rather than an independently verified biography or an announcement that an award has been granted. Researcher identities, institutional affiliations, publication records, and award outcomes should be confirmed through their respective authoritative sources before publication.

Research Profile

The supplied information identifies M. Ali Nasseri with the Technical University of Munich in Germany and associates the profile with Medicine and Health Sciences. It reports 78 documents, 1,160 citations, and an h-index of 19. These values are presented as user-provided figures and have not been independently verified for this article. Researcher databases may display different values depending on author disambiguation, database coverage, document types, citation-update dates, and profile-merging practices.[1][2]

The supplied ORCID identifier is 0000-0002-9764-5731. ORCID provides persistent researcher identifiers that can help distinguish scholars with similar names and connect them to their research outputs. An ORCID record may contain information entered by the researcher or added through authorized integrations; its contents should therefore be reviewed directly when verifying a person’s biography, affiliations, and publications.[2]

Research Contributions

Assessing a researcher’s contributions requires examining the substance of their scholarly work, including the questions investigated, the methods applied, the reliability of the findings, and the relevance of the results to the wider research community. In medicine and health sciences, additional considerations may include clinical significance, patient safety, ethical oversight, transparent reporting, and the extent to which findings can be reproduced or translated into practice.[3][4]

The supplied profile does not include a verified publication list, individual study titles, abstracts, or a detailed research statement. Accordingly, specific discoveries, clinical advances, inventions, or methodological innovations cannot be attributed to M. Ali Nasseri on the basis of the available information alone. A reliable account of research contributions should be prepared after reviewing the researcher’s verified publications and relevant supporting evidence.

Publications

The supplied Scopus profile information reports 78 documents. This figure is included as provided and should not be treated as a confirmed current total until the linked author record has been checked. A document count may include different publication types, and a researcher’s database profile may contain records that require author-level verification to distinguish their own work from that of other researchers with similar names.[1]

A publication list suitable for an academic recognition profile should include verified bibliographic details, such as author names, article title, journal or conference title, year of publication, volume and issue where applicable, page range or article number, and DOI when available. Publications should be selected for relevance and evidentiary value rather than solely for citation frequency. No individual publication titles or DOI identifiers have been supplied for this profile, so specific articles cannot be listed reliably here.

For additional verification, the researcher’s Scopus record and ORCID profile may be consulted through the external links below. The Scopus identifier in the supplied infobox is 55849349900, while the provided profile URL contains a different author identifier, 55322962400, in its displayed link text. This discrepancy should be resolved before publication to ensure that the correct author record is linked. The URL used in this article follows the identifier 55849349900 supplied for the profile.

Research Impact

The supplied bibliometric figures are 1,160 citations and an h-index of 19 across 78 documents. The h-index is a citation-based indicator that combines publication output with citation frequency: a value of 19 generally means that at least 19 indexed publications have each received at least 19 citations within the database and at the time of measurement. The indicator does not directly measure methodological quality, originality, societal value, or the clinical importance of research.[5]

Citation counts can vary across scholarly databases because each service indexes different journals, proceedings, books, and other research outputs. They can also change over time as new publications are indexed and citation records are updated. For a fair assessment, the database, retrieval date, author identity, and calculation method should be documented. Quantitative indicators should be interpreted alongside expert assessment and evidence of the researcher’s actual contributions.[3][5]

Research impact may extend beyond citations to include changes in professional practice, contributions to clinical guidance, data and software resources, interdisciplinary collaboration, public health outcomes, and knowledge dissemination. These dimensions require appropriate evidence and should not be inferred from citation metrics alone.

Award Suitability

The International Research Hypothesis Excellence Award is the event identified for this profile. The supplied information provides a basis for organizing the researcher’s stated bibliometric indicators within an academic recognition page. However, these figures alone are not sufficient to determine eligibility, establish award suitability, or confirm that the researcher has received an award.

A balanced evaluation for an innovative research award could consider the originality and significance of the research hypothesis, the quality of supporting evidence, methodological rigor, reproducibility, ethical compliance, publication record, contribution to the relevant field, and potential for advancing scientific understanding. Where applicable, reviewers may also consider translational relevance, interdisciplinary value, and documented benefits to health or society. These are general assessment considerations, not a claim about the event’s official criteria.[3][4]

Before a final award-related statement is published, the organizers’ official eligibility rules and evaluation procedures should be consulted. The candidate’s identity, affiliation, publication record, and supporting documentation should be verified, and any selection outcome should be reported only when confirmed by the award organizers. This approach distinguishes an informational research profile from a formal award announcement.

Conclusion

This academic profile summarizes the information supplied for M. Ali Nasseri, including the stated affiliation with the Technical University of Munich, the subject area of Medicine and Health Sciences, and the reported bibliometric figures of 78 documents, 1,160 citations, and an h-index of 19. These details provide a structured starting point for researcher identification and academic recognition. They should be confirmed against authoritative records before being treated as current or independently established facts.

A defensible assessment of innovative research requires more than publication and citation totals. Verified scholarly outputs, transparent methodology, originality, reproducibility, ethical standards, and demonstrable contributions to the field are important components of a comprehensive review. The profile should therefore be updated with verified publications, relevant DOI records, and confirmed award information as those details become available.

References

  1. Elsevier. (n.d.). Scopus Author Search and author profiles. Scopus. Consult the author record to verify the researcher’s identifier, indexed documents, citations, and h-index.
    https://www.scopus.com/
  2. ORCID. (n.d.). ORCID: Connecting research and researchers. ORCID provides persistent identifiers that help distinguish researchers and connect them with scholarly outputs.
    https://orcid.org/
  3. Hicks, D., Wouters, P., Waltman, L., de Rijcke, S., & Rafols, I. (2015). Bibliometrics: The Leiden Manifesto for research metrics. Nature, 520, 429–431.
    DOI: https://doi.org/10.1038/520429a
  4. San Francisco Declaration on Research Assessment (DORA). (2012; subsequent updates available). Declaration on Research Assessment. DORA advocates evaluating research on its merits and avoiding overreliance on journal-based metrics.
    https://sfdora.org/read/
  5. Hirsch, J. E. (2005). An index to quantify an individual’s scientific research output. Proceedings of the National Academy of Sciences, 102(46), 16569–16572.
    DOI: https://doi.org/10.1073/pnas.0507655102

Liwu Fu | Pharmacology | Best Researcher Award

Prof. Liwu Fu | Pharmacology | Best Researcher Award

Professor at Sun Yat-sen University Cancer Center, China

Liwu Fu, PhD, MD is a Professor and Director at the Cancer Institute, Cancer Center, Sun Yat-sen University, Guangzhou, China. πŸŽ“ He earned his MD from Guangdong Medical and Pharmaceutical College, followed by an MS and PhD in Medicine from Sun Yat-sen University. πŸ₯ Dr. Fu completed a postdoctoral fellowship at the Medical University of South Carolina, USA. His research focuses on anticancer drug development and cancer pathophysiology. πŸ”¬ With extensive experience in oncology and toxicology, he has held key academic and research positions since 1987.

Publication Profile

Scopus

πŸŽ“ Educational Background

πŸ“Œ Liwu Fu has a strong academic foundation in medicine and cancer research. He earned his MD from Guangdong Medical and Pharmaceutical College (1987) πŸ₯. He then pursued an MS in Medicine (1993) and a PhD in Medicine (1996) at Sun Yat-sen University, specializing in toxicology and cancer research πŸ”¬. Further advancing his expertise, he completed a postdoctoral fellowship (1999-2002) at the Medical University of South Carolina, USA, in pathology and laboratory medicine 🧬. His extensive education has shaped his contributions to oncology and anticancer drug development.Β πŸŽ—οΈ

πŸ’Ό Professional Experience

πŸ”¬ Liwu Fu is a Professor and Director at the Cancer Institute, Cancer Center, Sun Yat-sen University (since 2002) πŸ₯. He previously served as an Associate Professor (1998-2002) and Lecturer, Deputy Head (1996-1998) in the Department of Anticancer Drug. His research was further enriched by a postdoctoral fellowship at the Medical University of South Carolina, USA (1999-2002) πŸ‡ΊπŸ‡Έ. He has held key leadership roles, including Chairman of the Guangdong Cancer Pharmacological Society (since 2009) and Associate Director in multiple national cancer and pharmacology organizations πŸŽ—οΈ. He is also an AACR member and has contributed significantly to cancer pharmacology. πŸš€

Research Focus

Dr. Liwu Fu’s research focuses on cancer biology πŸ”¬, particularly in tumor immunology 🧬, drug resistance mechanisms πŸ’Š, and targeted therapies 🎯. His studies explore immune evasion through PD-L1 regulation, the role of extracellular vesicles in chemoresistance, and cancer stem cell-derived signals. He has contributed significantly to understanding lung cancer 🫁, colorectal cancer πŸ₯, and leukemia πŸ§‘β€βš•οΈ. His work also investigates innovative drug strategies like ERK and KRAS inhibitors, enhancing immune checkpoint therapies. His publications in high-impact journals demonstrate expertise in molecular oncology 🧫 and precision medicine 🏹, making key advancements in overcoming cancer treatment resistance.

Publication Top Notes

πŸ“Œ Intra-tumoral Sphingobacterium multivorum Promotes Triple-Negative Breast Cancer Progression by Suppressing Tumor Immunosurveillance
πŸ—“ Year: 2025 |Β  Cited by: 2 |Β  Molecular Cancer

πŸ“Œ Effect of Extracellular Vesicles Derived From Tumor Cells on Immune Evasion
πŸ—“ Year: 2025 |Β Advanced Science

πŸ“Œ Resistance to Antibody–Drug Conjugates: A Review
πŸ—“ Year: 2025 | Acta Pharmaceutica Sinica B

πŸ“Œ PBA2, a Novel Inhibitor of the Ξ²-Catenin/CBP Pathway, Eradicates Chronic Myeloid Leukemia Including BCR-ABL T315I Mutation
πŸ—“ Year: 2024 |Β Molecular Cancer

πŸ“Œ BI-2865, a Pan-KRAS Inhibitor, Reverses the P-Glycoprotein Induced Multidrug Resistance In Vitro and In Vivo
πŸ—“ Year: 2024 | Β Cited by: 2 | Β Cell Communication and Signaling

Conclusion

Professor Liwu Fu is a distinguished cancer researcher specializing in pharmacology, chemotherapy, multidrug resistance, and personalized cancer therapy. With over 200 publications in high-impact SCI journals and leadership in 40+ major research projects, his contributions to oncology are widely recognized. He has received prestigious honors, including the Chinese Anti-Cancer Association Science and Technology Award, and holds key roles in national and international cancer research organizations. Additionally, he serves on the editorial boards of top-tier cancer research journals and reviews for esteemed publications like Cancer Research and Journal of Pharmacology and Experimental Therapeutics. His groundbreaking work in overcoming multidrug resistance positions him as a strong candidate for the Best Researcher Award. πŸš€πŸ†